Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Michael

Showing results (941-950 of 1,111) with videos related to

Pageof 112
Sort By:
Ebiomedicine|January 20, 2015
Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting VirusesSusan Zolla-Pazner, Paul T Edlefsen, Morgane Rolland, et al.
Plos One|December 30, 2011
Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in ThailandPunnee Pitisuttithum, Supachai Rerks-Ngarm, Valai Bussaratid, et al.
Ebiomedicine|July 29, 2022
Dissecting drivers of immune activation in chronic HIV-1 infectionHendrik Streeck, Alvino Maestri, Daniel Habermann, et al.
Nature Immunology|September 24, 2021
The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccinationJeffrey Alan Tomalka, Adam Nicolas Pelletier, Slim Fourati, et al.
Ebiomedicine|November 8, 2023
Tracking coreceptor switch of the transmitted/founder HIV-1 identifies co-evolution of HIV-1 antigenicity, coreceptor usage and CD4 subset targeting: the RV217 acute infection cohort studyManukumar Honnayakanahalli Marichannegowda, Michelle Zemil, Lindsay Wieczorek, et al.
Plos One|July 6, 2017
V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144Lautaro G Perez, David R Martinez, Allan C deCamp, et al.
Journal of Virology|April 12, 2013
Molecular evolution of the HIV-1 Thai epidemic between the time of RV144 immunogen selection to the execution of the vaccine efficacy trialGustavo H Kijak, Sodsai Tovanabutra, Supachai Rerks-Ngarm, et al.
Science Translational Medicine|February 17, 2017
Delayed differentiation of potent effector CD8<sup>+</sup> T cells reducing viremia and reservoir seeding in acute HIV infectionHiroshi Takata, Supranee Buranapraditkun, Cari Kessing, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Tracking coreceptor switch of the transmitted/founder HIV-1 identifies co-evolution of HIV-1 antigenicity, coreceptor usage and CD4 subset targetingManukumar Honnayakanahalli Marichannegowda, Michelle Zemil, Lindsay Wieczorek, et al.
Behaviour Research and Therapy|October 28, 2017
The ENGAGE study: Integrating neuroimaging, virtual reality and smartphone sensing to understand self-regulation for managing depression and obesity in a precision medicine modelLeanne M Williams, Adam Pines, Andrea N Goldstein-Piekarski, et al.
Pageof 112

Showing results (941-950 of 1,111) with videos related to

Sort By:
Pageof 112
Ebiomedicine|January 20, 2015
Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting VirusesSusan Zolla-Pazner, Paul T Edlefsen, Morgane Rolland, et al.
Plos One|December 30, 2011
Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in ThailandPunnee Pitisuttithum, Supachai Rerks-Ngarm, Valai Bussaratid, et al.
Ebiomedicine|July 29, 2022
Dissecting drivers of immune activation in chronic HIV-1 infectionHendrik Streeck, Alvino Maestri, Daniel Habermann, et al.
Nature Immunology|September 24, 2021
The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccinationJeffrey Alan Tomalka, Adam Nicolas Pelletier, Slim Fourati, et al.
Ebiomedicine|November 8, 2023
Tracking coreceptor switch of the transmitted/founder HIV-1 identifies co-evolution of HIV-1 antigenicity, coreceptor usage and CD4 subset targeting: the RV217 acute infection cohort studyManukumar Honnayakanahalli Marichannegowda, Michelle Zemil, Lindsay Wieczorek, et al.
Plos One|July 6, 2017
V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144Lautaro G Perez, David R Martinez, Allan C deCamp, et al.
Journal of Virology|April 12, 2013
Molecular evolution of the HIV-1 Thai epidemic between the time of RV144 immunogen selection to the execution of the vaccine efficacy trialGustavo H Kijak, Sodsai Tovanabutra, Supachai Rerks-Ngarm, et al.
Science Translational Medicine|February 17, 2017
Delayed differentiation of potent effector CD8<sup>+</sup> T cells reducing viremia and reservoir seeding in acute HIV infectionHiroshi Takata, Supranee Buranapraditkun, Cari Kessing, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Tracking coreceptor switch of the transmitted/founder HIV-1 identifies co-evolution of HIV-1 antigenicity, coreceptor usage and CD4 subset targetingManukumar Honnayakanahalli Marichannegowda, Michelle Zemil, Lindsay Wieczorek, et al.
Behaviour Research and Therapy|October 28, 2017
The ENGAGE study: Integrating neuroimaging, virtual reality and smartphone sensing to understand self-regulation for managing depression and obesity in a precision medicine modelLeanne M Williams, Adam Pines, Andrea N Goldstein-Piekarski, et al.
Pageof 112